Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
Cisplatin and its analogs are among the most widely used chemotherapeutic agents against various types of cancer. It is known that cisplatin can activate epidermal growth factor receptor (EGFR), which may provide a survival benefit in cancers. Tetrathiomolybdate (TM) is a potent anti-cancer and anti...
Main Authors: | Kim, Kyu Kwang, Han, Alex, Yano, Naohiro, Ribeiro, Jennifer R., Lokich, Elizabeth, Singh, Rakesh K., Moore, Richard G. |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644948/ |
Similar Items
-
Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells
by: Kwang Kim, Kyu, et al.
Published: (2015) -
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
by: Kim, Kyu Kwang, et al.
Published: (2012) -
HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation
by: Lokich, Elizabeth, et al.
Published: (2014) -
Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
by: XIE, YA, et al.
Published: (2014) -
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
by: Ribeiro, J. R., et al.
Published: (2016)